Unicycive Therapeutics Inc (UNCY NASDAQ) stock market data APIs
$5.4849
-0.04(-0.7%)
as of August 14, 2026
Try our APIs with
free plan!
Unicycive Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Prev. Close
5.4849
Open
5.4449
High
5.6113
Low
5.4445
52 wk Range
3.71-8.74
Market Cap
148 M
Shares Outstanding
27 393 K
EPS
-0.06
Beta
1.782
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Unicycive Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at €19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only €19.99
TRY NOW
Get Unicycive Therapeutics Inc data using free add-ons & libraries
Get Unicycive Therapeutics Inc Fundamental Data
Unicycive Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -33 094 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
€
59.99
/mo.
End-of-day & Earnings data
Get Unicycive Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
€
19.99
/mo.
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -0.34
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Unicycive Therapeutics Inc News
New
UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation
BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Unicycive Therapeutics, Inc. (Nasdaq: UNCY) for potential securities law violations. Investors who have lost money in their...
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.
NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:...
UNCY SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”...
Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Unicycive Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options If you purchased or acquire...
Get Unicycive Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
€19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only €19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
€99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
